SCHEMBL2903384

SCHEMBL2903384

CCCOc1ccccc1C(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.55
KMT2A Q03164 3/20 0.55
MEN1 O00255 2/20 0.55
CYP1A2 P05177 2/20 0.55
CYP2C9 P11712 2/20 0.55
CYP2C19 P33261 2/20 0.55
CYP3A4 P08684 1/20 0.55
RECQL P46063 1/20 0.55
LMNA P02545 4/20 0.54
ALDH1A1 P00352 2/20 0.54
PTGES O14684 1/20 0.47
ALOX5 P09917 1/20 0.47
PPARG P37231 1/20 0.47
PPARA Q07869 1/20 0.47
NISCH Q9Y2I1 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
KDM4E B2RXH2 1/20 0.44
ATM Q13315 1/20 0.43
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9226775 0.90 L3MBTL1 (0.58) L3MBTL1KMT2AMEN1CYP1A2CYP2C9
SCHEMBL18309270 0.90 L3MBTL1 (0.60) L3MBTL1KMT2AMEN1CYP1A2CYP2C9
SCHEMBL9214705 0.87 LMNA (0.61) L3MBTL1KMT2AMEN1CYP1A2CYP2C9
SCHEMBL254754 0.85 ALDH1A1 (0.54) L3MBTL1KMT2AMEN1CYP1A2CYP2C9
SCHEMBL22500372 0.85 L3MBTL1 (0.60) L3MBTL1KMT2AMEN1CYP1A2CYP2C9
SCHEMBL10511897 0.85 L3MBTL1 (0.44) L3MBTL1KMT2AMEN1CYP1A2CYP2C9
SCHEMBL18309273 0.84 L3MBTL1 (0.55) L3MBTL1KMT2AMEN1CYP1A2CYP2C9
Hydrochloric Acid SCHEMBL21879697 0.83 CYP1A2 (0.44) L3MBTL1KMT2AMEN1CYP1A2CYP2C9
SCHEMBL74286 0.83 L3MBTL1 (0.48) L3MBTL1KMT2AMEN1CYP1A2CYP2C9
SCHEMBL12250772 0.83 L3MBTL1 (0.48) L3MBTL1KMT2AMEN1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230135560-A1 GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2023-05-04 US disclosed
US-20230135560-A1 GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2023-05-04 US disclosed
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
WO-2022149617-A1 COMPOUND LIBRARY 中外製薬株式会社 2022-07-14 WO disclosed
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-08-05 US disclosed
US-20210059798-A1 SHADE MATCHING DENTAL COMPOSITE BRINGLEY JOSEPH F (US) 2021-03-04 US disclosed
US-20210002254-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-01-07 US disclosed
US-10766877-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-09-08 US disclosed
US-20200216415-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2020-07-09 US disclosed
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-31 US disclosed
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2010-01-14 US disclosed
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS BRAINCELLS, INC. (US) 2010-01-14 US disclosed
WO-2010003026-A1 METHODS FOR EXTENSIVE DARK CURING BASED ON VISIBLE-LIGHT INITIATED, CONTROLLED RADICAL POLYMERIZATION THE REGENTS OF THE UNIVERSITY OF COLORADO (US) 2010-01-07 WO disclosed
WO-2009058843-A2 DENTAL COMPOSITIONS AND INITIATOR SYSTEMS WITH COLOR-STABLE AMINE ELECTRON DONORS 3M INNOVATIVE PROPERTIES COMPANY (US) 2009-05-07 WO disclosed
CN-101170985-A Hardenable antimicrobial dental compositions and methods 3M INNOVATIVE PROPERTIES CO (US) 2008-04-30 CN disclosed
US-20080009498-A1 Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use NITROMED, INC. (US) 2008-01-10 US disclosed
EP-1578377-A1 COMPOSITIONS INCLUDING POLYMERIZABLE BISPHOSPHONIC ACIDS AND METHODS 3M Innovative Properties Company (US) 2005-09-28 EP disclosed
EP-1459132-A1 MULTIPHOTON PHOTOSENSITIZATION SYSTEM 3M Innovative Properties Company (US) 2004-09-22 EP disclosed
WO-2004060327-A1 COMPOSITIONS INCLUDING POLYMERIZABLE BISPHOSPHONIC ACIDS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2004-07-22 WO disclosed
WO-2003058346-A1 MULTIPHOTON PHOTOSENSITIZATION SYSTEM 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R L3MBTL1 4237/4885KMT2A 1341/4885MEN1 644/4885
US-20100009983-A1 5 HT RECEPTOR MEDIATED NEUROGENESIS HTR6, GAP43, HTR5A L3MBTL1 4493/4885KMT2A 2847/4885MEN1 4080/4885
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R L3MBTL1 4237/4885KMT2A 1341/4885MEN1 644/4885
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R L3MBTL1 4237/4885KMT2A 1341/4885MEN1 644/4885
US-20080009498-A1 Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use PDE3A, PDE3B, PDE2A L3MBTL1 4601/4885KMT2A 3848/4885MEN1 2960/4885
US-20230135560-A1 GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC1R, MC3R, MC2R L3MBTL1 4621/4885KMT2A 1137/4885MEN1 920/4885
US-20210002254-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R L3MBTL1 4237/4885KMT2A 1341/4885MEN1 644/4885
US-10766877-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R L3MBTL1 4237/4885KMT2A 1341/4885MEN1 644/4885
US-20200216415-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R L3MBTL1 4237/4885KMT2A 1341/4885MEN1 644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.